<p>Roivant Sciences Ltd.（纳斯达克代码：ROIV - 获取免费报告）主要股东 Vivek Ramaswamy 于 5 月 6 日星期二出售了 273,959 股该公司的股票。股票以平均价格 11.47 美元出售，总交易额为 3,142,309.73 美元。出售后，该内部人士现在直接持有 39,799,611 股公司股票，价值 456,501,538.17 美元。此次交易使其持股减少了 0.68%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。持有公司股票超过 10% 的主要股东需向证券交易委员会披露其交易。</p>
<p>获取 <strong>Roivant Sciences</strong> 警报：</p>
<h2>Roivant Sciences 股票表现</h2>
<ul>
<li>特朗普指数：与特朗普内阁相关的 6 家公司值得关注</li>
</ul>
<p>Roivant Sciences 的股票在周五开盘价为 11.03 美元。该公司的 50 日移动平均价格为 10.48 美元，200 日移动平均价格为 11.12 美元。该股票的市值为 78.7 亿美元，市盈率为-73.53，贝塔值为 1.23。Roivant Sciences Ltd.的 1 年最低价为 8.73 美元，1 年最高价为 13.06 美元。</p>
<p>Roivant Sciences（纳斯达克代码：ROIV - 获取免费报告）最近于 2 月 10 日星期一发布了其财报。公司报告本季度每股收益（EPS）为-0.20 美元，超出分析师一致预期的-0.24 美元，超出幅度为 0.04 美元。Roivant Sciences 的净利润率为-119.54%，股本回报率为-14.05%。卖方分析师预测 Roivant Sciences Ltd.在当前年度将发布-0.92 美元的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究分析师对该股票发表了看法。Cantor Fitzgerald 在 3 月 4 日星期二的报告中将 Roivant Sciences 的股票评级上调至 “强力买入”。HC Wainwright 在 4 月 21 日星期一的研究报告中重申了 “买入” 评级，并对 Roivant Sciences 的股票设定了 18.00 美元的目标价。</p>
<p><strong>查看我们最新的 Roivant Sciences 股票报告</strong></p>
<h2>对 Roivant Sciences 的对冲基金看法</h2>
<p>多家对冲基金最近对 ROIV 的持仓进行了调整。Parallel Advisors LLC 在第一季度将其在 Roivant Sciences 的股份增加了 80.5%。Parallel Advisors LLC 现在持有 2,485 股该公司的股票，价值 25,000 美元，此前在上个季度增持了 1,108 股。Russell Investments Group Ltd.在第四季度将其在 Roivant Sciences 的持仓增加了 478.6%。Russell Investments Group Ltd.现在持有 2,355 股该公司的股票，价值 28,000 美元，此前在上个季度增持了 1,948 股。Aster Capital Management DIFC Ltd 在第四季度新购入了 Roivant Sciences 的股份，价值 39,000 美元。GAMMA Investing LLC 在第四季度将其在 Roivant Sciences 的股份增加了 57.0%。GAMMA Investing LLC 现在持有 3,548 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 1,288 股。最后，UMB Bank n.a.在第一季度将其在 Roivant Sciences 的持仓增加了 112.7%。UMB Bank n.a.现在持有 4,143 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 2,195 股。机构投资者和对冲基金持有该公司 64.76% 的股份。</p>
<h2>Roivant Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Roivant Sciences Ltd.是一家商业阶段的生物制药公司，专注于开发和商业化针对炎症和免疫学领域的药物。该公司提供 Vants，一种开发和商业化其药物和技术的模型，专注于生物制药业务、发现阶段公司和健康科技初创企业。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Roivant Sciences</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克关闭时间</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>最佳航空航天股票投资</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>股票平均计算器</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Roivant Sciences 吗？</h2>
<p>在考虑 Roivant Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Roivant Sciences 并不在名单上。</p>
<p>虽然 Roivant Sciences 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ROIV

<p>Vivek Ramaswamy，Roivant Sciences Ltd.（纳斯达克代码：ROIV）的主要股东，出售了 273,959 股，平均价格为 11.47 美元，总计 3,142,309.73 美元。出售后，他持有 39,799,611 股，价值约为 4.565 亿美元，持股比例减少了 0.68%。该交易已向美国证券交易委员会（SEC）披露。Roivant Sciences 的市值为 78.7 亿美元，在最近的财报中报告每股收益为负（0.20 美元）。分析师对该股票的评级不一，有些人预测其将实现增长</p>

<p>Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now directly owns 39,799,611 shares in the company, valued at $456,501,538.17. The trade was a 0.68 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.</p>
<div class="lb-trans"><p>Roivant Sciences Ltd.（纳斯达克代码：ROIV - 获取免费报告）主要股东 Vivek Ramaswamy 于 5 月 6 日星期二出售了 273,959 股该公司的股票。股票以平均价格 11.47 美元出售，总交易额为 3,142,309.73 美元。出售后，该内部人士现在直接持有 39,799,611 股公司股票，价值 456,501,538.17 美元。此次交易使其持股减少了 0.68%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。持有公司股票超过 10% 的主要股东需向证券交易委员会披露其交易。</p>
</div><p>Get <strong>Roivant Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Roivant Sciences</strong> 警报：</p>
</div><h2>Roivant Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Roivant Sciences 股票表现</h2>
</div><ul>
<li>Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普指数：与特朗普内阁相关的 6 家公司值得关注</li>
</ul>
</div><p>Roivant Sciences stock opened at $11.03 on Friday. The company's fifty day moving average price is $10.48 and its 200 day moving average price is $11.12. The stock has a market capitalization of $7.87 billion, a P/E ratio of -73.53 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06.</p>
<div class="lb-trans"><p>Roivant Sciences 的股票在周五开盘价为 11.03 美元。该公司的 50 日移动平均价格为 10.48 美元，200 日移动平均价格为 11.12 美元。该股票的市值为 78.7 亿美元，市盈率为-73.53，贝塔值为 1.23。Roivant Sciences Ltd.的 1 年最低价为 8.73 美元，1 年最高价为 13.06 美元。</p>
</div><p>Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.</p>
<div class="lb-trans"><p>Roivant Sciences（纳斯达克代码：ROIV - 获取免费报告）最近于 2 月 10 日星期一发布了其财报。公司报告本季度每股收益（EPS）为-0.20 美元，超出分析师一致预期的-0.24 美元，超出幅度为 0.04 美元。Roivant Sciences 的净利润率为-119.54%，股本回报率为-14.05%。卖方分析师预测 Roivant Sciences Ltd.在当前年度将发布-0.92 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have weighed in on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a &#34;strong-buy&#34; rating in a report on Tuesday, March 4th. HC Wainwright restated a &#34;buy&#34; rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st.</p>
<div class="lb-trans"><p>多家研究分析师对该股票发表了看法。Cantor Fitzgerald 在 3 月 4 日星期二的报告中将 Roivant Sciences 的股票评级上调至 “强力买入”。HC Wainwright 在 4 月 21 日星期一的研究报告中重申了 “买入” 评级，并对 Roivant Sciences 的股票设定了 18.00 美元的目标价。</p>
</div><p><strong>View Our Latest Stock Report on Roivant Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Roivant Sciences 股票报告</strong></p>
</div><h2>Hedge Funds Weigh In On Roivant Sciences</h2>
<div class="lb-trans"><h2>对 Roivant Sciences 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in ROIV. Parallel Advisors LLC boosted its stake in shares of Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after acquiring an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences during the 4th quarter worth $39,000. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.</p>
<div class="lb-trans"><p>多家对冲基金最近对 ROIV 的持仓进行了调整。Parallel Advisors LLC 在第一季度将其在 Roivant Sciences 的股份增加了 80.5%。Parallel Advisors LLC 现在持有 2,485 股该公司的股票，价值 25,000 美元，此前在上个季度增持了 1,108 股。Russell Investments Group Ltd.在第四季度将其在 Roivant Sciences 的持仓增加了 478.6%。Russell Investments Group Ltd.现在持有 2,355 股该公司的股票，价值 28,000 美元，此前在上个季度增持了 1,948 股。Aster Capital Management DIFC Ltd 在第四季度新购入了 Roivant Sciences 的股份，价值 39,000 美元。GAMMA Investing LLC 在第四季度将其在 Roivant Sciences 的股份增加了 57.0%。GAMMA Investing LLC 现在持有 3,548 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 1,288 股。最后，UMB Bank n.a.在第一季度将其在 Roivant Sciences 的持仓增加了 112.7%。UMB Bank n.a.现在持有 4,143 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 2,195 股。机构投资者和对冲基金持有该公司 64.76% 的股份。</p>
</div><h2>Roivant Sciences Company Profile</h2>
<div class="lb-trans"><h2>Roivant Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.</p>
<div class="lb-trans"><p>Roivant Sciences Ltd.是一家商业阶段的生物制药公司，专注于开发和商业化针对炎症和免疫学领域的药物。该公司提供 Vants，一种开发和商业化其药物和技术的模型，专注于生物制药业务、发现阶段公司和健康科技初创企业。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Roivant Sciences</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li>
<li>Best Aerospace Stocks Investing</li>
<li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li>
<li>Stock Average Calculator</li>
<li>Is Energy Transfer Undervalued or a Value Trap?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Roivant Sciences</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克关闭时间</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>最佳航空航天股票投资</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>股票平均计算器</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ROIV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Roivant Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Roivant Sciences 吗？</h2>
</div><p>Before you consider Roivant Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Roivant Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Roivant Sciences 并不在名单上。</p>
</div><p>While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Roivant Sciences 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Vivek Ramaswamy 出售了 273,959 股 Roivant Sciences Ltd.（纳斯达克股票代码：ROIV）的股票